Published in Antimicrob Agents Chemother on November 01, 1994
DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev (1997) 9.69
Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother (1996) 7.10
Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother (1995) 5.64
Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother (1996) 4.42
Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J Bacteriol (1996) 4.34
Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob Agents Chemother (1996) 4.15
Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother (1996) 3.86
Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob Agents Chemother (1997) 3.83
Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli. Antimicrob Agents Chemother (1996) 2.91
Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1996) 2.84
Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob Agents Chemother (1996) 2.48
Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene. Antimicrob Agents Chemother (1996) 2.42
Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases. Antimicrob Agents Chemother (1996) 2.31
Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli. Antimicrob Agents Chemother (1999) 1.99
Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1995) 1.84
Quinolones: from antibiotics to autoinducers. FEMS Microbiol Rev (2011) 1.75
Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus. Antimicrob Agents Chemother (1997) 1.70
Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci. Antimicrob Agents Chemother (1998) 1.58
Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro. Antimicrob Agents Chemother (2000) 1.45
Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins. Antimicrob Agents Chemother (1999) 1.34
In vitro and in vivo antifungal activities of DU-6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi. Antimicrob Agents Chemother (1995) 1.12
Mechanism of differential activities of ofloxacin enantiomers. Antimicrob Agents Chemother (1996) 1.07
Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms. Antimicrob Agents Chemother (1999) 1.06
Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases. Antimicrob Agents Chemother (1998) 1.01
DNA cleavage activities of Staphylococcus aureus gyrase and topoisomerase IV stimulated by quinolones and 2-pyridones. Antimicrob Agents Chemother (1999) 0.99
Molecular cloning of the gyrA and gyrB genes of Bacteroides fragilis encoding DNA gyrase. Antimicrob Agents Chemother (1999) 0.98
Studies on the antimicrobial properties of N-acylated ciprofloxacins. Bioorg Med Chem Lett (2012) 0.97
Glycosylated flavones as selective inhibitors of topoisomerase IV. Antimicrob Agents Chemother (1997) 0.97
Antibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type II topoisomerases. Antimicrob Agents Chemother (1998) 0.95
Cloning, expression, and enzymatic characterization of Pseudomonas aeruginosa topoisomerase IV. Antimicrob Agents Chemother (1999) 0.91
Italian survey on comparative levofloxacin susceptibility in 334 clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1999) 0.83
The new fluoroquinolones: A critical review. Can J Infect Dis (1999) 0.82
NorA plasmid resistance to fluoroquinolones: role of copy number and norA frameshift mutations. Antimicrob Agents Chemother (1996) 0.81
Antimicrobial properties of 8-hydroxyserrulat-14-en-19-oic acid for treatment of implant-associated infections. Antimicrob Agents Chemother (2012) 0.79
Accumulation of norfloxacin by Mycobacterium aurum and Mycobacterium smegmatis. Antimicrob Agents Chemother (1998) 0.78
Functional Analyses of the Toxoplasma gondii DNA Gyrase Holoenzyme: A Janus Topoisomerase with Supercoiling and Decatenation Abilities. Sci Rep (2015) 0.78
Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens. Eur J Clin Microbiol Infect Dis (1998) 0.77
Synthesis, structure-activity relationship studies, and antibacterial evaluation of 4-chromanones and chalcones, as well as olympicin A and derivatives. J Med Chem (2014) 0.77
Gyrase inhibitors and thymine starvation disrupt the normal pattern of plasmid RK2 localization in Escherichia coli. J Bacteriol (2005) 0.75
Contribution of the ATP binding site of ParE to susceptibility to novobiocin and quinolones in Streptococcus pneumoniae. J Bacteriol (2005) 0.75
Treatment outcomes of oral sitafloxacin in acute complicated urinary tract infection and pyelonephritis. Springerplus (2016) 0.75
DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc Natl Acad Sci U S A (1976) 17.42
Supercoiling of the DNA template during transcription. Proc Natl Acad Sci U S A (1987) 14.25
Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother (1990) 11.71
Interaction between DNA and an Escherichia coli protein omega. J Mol Biol (1971) 11.03
New topoisomerase essential for chromosome segregation in E. coli. Cell (1990) 7.19
Escherichia coli DNA topoisomerase I mutants have compensatory mutations in DNA gyrase genes. Cell (1982) 6.11
Escherichia coli DNA topoisomerase I mutants: increased supercoiling is corrected by mutations near gyrase genes. Cell (1982) 4.62
Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions. J Biol Chem (1993) 4.54
Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob Agents Chemother (1992) 4.43
The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replication. Cell (1992) 3.88
DNA topoisomerases: why so many? J Biol Chem (1991) 3.28
Synthesis and antibacterial activities of optically active ofloxacin. Antimicrob Agents Chemother (1986) 2.74
Bacterial chromosome segregation: evidence for DNA gyrase involvement in decatenation. Cell (1984) 2.58
Purification and characterization of DNA topoisomerase IV in Escherichia coli. J Biol Chem (1992) 2.50
Control of bacterial DNA supercoiling. Mol Microbiol (1992) 2.47
Gene organization in the region containing a new gene involved in chromosome partition in Escherichia coli. J Bacteriol (1988) 2.31
Identification of a potent decatenating enzyme from Escherichia coli. J Biol Chem (1988) 2.19
Catenation of DNA rings by topoisomerases. Mechanism of control by spermidine. J Biol Chem (1982) 2.18
Limitations of plasmid complementation test for determination of quinolone resistance due to changes in the gyrase A protein and identification of conditional quinolone resistance locus. Antimicrob Agents Chemother (1993) 2.04
Decatenation activity of topoisomerase IV during oriC and pBR322 DNA replication in vitro. Proc Natl Acad Sci U S A (1993) 1.91
Antimicrobial activity of DV-7751a, a new fluoroquinolone. Antimicrob Agents Chemother (1993) 1.86
Genetic analysis of mutations that compensate for loss of Escherichia coli DNA topoisomerase I. J Bacteriol (1985) 1.74
Molecular cloning and DNA sequence analysis of Escherichia coli topB, the gene encoding topoisomerase III. J Biol Chem (1989) 1.67
Escherichia coli DNA topoisomerase III: purification and characterization of a new type I enzyme. Biochemistry (1984) 1.63
Decatenating activity of Escherichia coli DNA gyrase and topoisomerases I and III during oriC and pBR322 DNA replication in vitro. J Biol Chem (1994) 1.58
DNA supercoiling in Escherichia coli: topA mutations can be suppressed by DNA amplifications involving the tolC locus. Mol Microbiol (1989) 1.47
Requirement of DNA gyrase for the initiation of chromosome replication in Escherichia coli K-12. Mol Gen Genet (1980) 1.45
Temperature-sensitive lethal mutant of era, a G protein in Escherichia coli. J Bacteriol (1989) 1.45
DNA supercoiling in gyrase mutants. J Bacteriol (1984) 1.40
The gyrB gene product functions in both initiation and chain polymerization of Escherichia coli chromosome replication: suppression of the initiation deficiency in gyrB-ts mutants by a class of rpoB mutations. Mol Gen Genet (1983) 1.37
Topoisomerase mutations affect the relative abundance of many Escherichia coli proteins. Mol Microbiol (1993) 1.25
Inhibitory effects of quinolones on pro- and eucaryotic DNA topoisomerases I and II. Antimicrob Agents Chemother (1990) 1.25
DNA gyrase-catalyzed decatenation of multiply linked DNA dimers. J Biol Chem (1987) 1.25
Chromosomal supercoiling in Escherichia coli. Mol Microbiol (1993) 1.22
Chromosome partitioning in Escherichia coli. J Bacteriol (1992) 1.14
Significance of the methyl group on the oxazine ring of ofloxacin derivatives in the inhibition of bacterial and mammalian type II topoisomerases. Antimicrob Agents Chemother (1991) 1.07
Antibacterial activity of ofloxacin and its mode of action. Infection (1986) 1.01
KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res (1999) 40.62
Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature (2002) 28.79
Functional annotation of a full-length mouse cDNA collection. Nature (2001) 23.61
In vitro and in vivo activity of DL-8280, a new oxazine derivative. Antimicrob Agents Chemother (1982) 21.31
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
Transducing fragments in generalized transduction by phage P1. I. Molecular origin of the fragments. J Mol Biol (1965) 7.72
Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell (1993) 7.19
T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature (2000) 6.49
Delineating developmental and metabolic pathways in vivo by expression profiling using the RIKEN set of 18,816 full-length enriched mouse cDNA arrays. Proc Natl Acad Sci U S A (2001) 6.07
Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol (1992) 5.93
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
Isolation and Identification of a Senescence-promoting Substance from Wormwood (Artemisia absinthium L.). Plant Physiol (1980) 5.37
Prophage P1, and extrachromosomal replication unit. Cold Spring Harb Symp Quant Biol (1968) 4.75
Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci U S A (1980) 4.66
Silencing factors participate in DNA repair and recombination in Saccharomyces cerevisiae. Nature (1997) 4.57
Genome sequence of an industrial microorganism Streptomyces avermitilis: deducing the ability of producing secondary metabolites. Proc Natl Acad Sci U S A (2001) 4.56
The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J (1996) 4.55
Changes in expression of murine leukemia virus antigens and production of xenotropic virus in the late preleukemic period in AKR mice. Proc Natl Acad Sci U S A (1976) 4.52
High-efficiency full-length cDNA cloning by biotinylated CAP trapper. Genomics (1996) 4.41
Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature (1999) 4.35
Avian sarcoma virus Y73 genome sequence and structural similarity of its transforming gene product to that of Rous sarcoma virus. Nature (1982) 4.33
Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol (1988) 4.20
In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob Agents Chemother (1988) 4.03
Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation (2001) 4.01
Isolation of human rotavirus in cell cultures: brief report. Arch Virol (1981) 3.83
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Purification and properties of DNA gyrase from a fluoroquinolone-resistant strain of Escherichia coli. Antimicrob Agents Chemother (1986) 3.69
Biochemical properties of beta-lactamase produced by Flavobacterium odoratum. Antimicrob Agents Chemother (1985) 3.62
Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest (1993) 3.57
Defining the functions of trans-SNARE pairs. Nature (1998) 3.52
On the process of cellular division in Escherichia coli: nucleotide sequence of the gene for penicillin-binding protein 3. Mol Gen Genet (1983) 3.43
Role of inorganic polyphosphate in promoting ribosomal protein degradation by the Lon protease in E. coli. Science (2001) 3.35
Breast cancer after exposure to the atomic bombings of Hiroshima and Nagasaki. N Engl J Med (1968) 3.29
Calcium movements, distribution, and functions in smooth muscle. Pharmacol Rev (1997) 3.23
Dentatorubral and pallidoluysian atrophy expansion of an unstable CAG trinucleotide on chromosome 12p. Nat Genet (1994) 3.17
Bloom's and Werner's syndrome genes suppress hyperrecombination in yeast sgs1 mutant: implication for genomic instability in human diseases. Proc Natl Acad Sci U S A (1998) 3.14
Relation of GIX antigen of thymocytes to envelope glycoprotein of murine leukemia virus. J Exp Med (1975) 3.06
Some properties of subunits of DNA gyrase from Pseudomonas aeruginosa PAO1 and its nalidixic acid-resistant mutant. J Bacteriol (1987) 3.04
Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J Clin Invest (2000) 2.96
Guanylin: an endogenous activator of intestinal guanylate cyclase. Proc Natl Acad Sci U S A (1992) 2.92
Alginate synthesis by Pseudomonas aeruginosa: a key pathogenic factor in chronic pulmonary infections of cystic fibrosis patients. Clin Microbiol Rev (1991) 2.87
Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res (1996) 2.86
Eight calves cloned from somatic cells of a single adult. Science (1998) 2.84
Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem (1994) 2.82
Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity (2000) 2.81
Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens (1998) 2.77
Activity of beta-lactamase produced by Bacteroides fragilis against newly introduced cephalosporins. Antimicrob Agents Chemother (1980) 2.76
Experimental investigation of geologically produced antineutrinos with KamLAND. Nature (2005) 2.75
Identification of various serovar strains of Mycobacterium avium complex by using DNA probes specific for Mycobacterium avium and Mycobacterium intracellulare. J Clin Microbiol (1990) 2.73
Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med (1998) 2.72
Chromatographic separation and antigenic analysis of proteins of the oncornaviruses. V. Identification of a new murine viral protein, p15(E). J Virol (1975) 2.72
Antagonistic action of imidazolineoxyl N-oxides against endothelium-derived relaxing factor/.NO through a radical reaction. Biochemistry (1993) 2.70
Change in receptor-binding specificity of recent human influenza A viruses (H3N2): a single amino acid change in hemagglutinin altered its recognition of sialyloligosaccharides. Virology (2000) 2.70
Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res (1991) 2.70
Fas ligand in human serum. Nat Med (1996) 2.53
Effect of N-formimidoyl thienamycin (MK0787) on beta-lactamases and activity against beta-lactamase-producing strains. Antimicrob Agents Chemother (1980) 2.53
RecQ DNA helicase is a suppressor of illegitimate recombination in Escherichia coli. Proc Natl Acad Sci U S A (1997) 2.51
Purification and characterization of DNA topoisomerase IV in Escherichia coli. J Biol Chem (1992) 2.50
Endoscopic submucosal dissection for early gastric cancer: results and degrees of technical difficulty as well as success. Endoscopy (2006) 2.48
Quantitation of hepatitis B virus genomic DNA by real-time detection PCR. J Clin Microbiol (1999) 2.46
Studies of novel transducing variants of lambda: dispensability of genes N and Q. Virology (1969) 2.44
Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene. Antimicrob Agents Chemother (1996) 2.42
Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nat Med (1998) 2.40
Identification and partial characterization of Mycobacterium avium and Mycobacterium intracellulare by using DNA probes. J Clin Microbiol (1989) 2.37
A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection. J Infect (2003) 2.36
Norfloxacin resistance in a clinical isolate of Escherichia coli. Antimicrob Agents Chemother (1987) 2.33
Purification, induction, and distribution of placental glutathione transferase: a new marker enzyme for preneoplastic cells in the rat chemical hepatocarcinogenesis. Proc Natl Acad Sci U S A (1985) 2.32
Submucosal endoscopic tumor resection for subepithelial tumors in the esophagus and cardia. Endoscopy (2012) 2.32
Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis. Gastroenterology (2001) 2.30
Fractionated stereotactic radiotherapy for choroidal melanoma. Radiother Oncol (1997) 2.29
Chronic inflammatory arthropathy associated with HTLV-I. Lancet (1989) 2.28
Functional expression and germline transmission of a human chromosome fragment in chimaeric mice. Nat Genet (1997) 2.28
Properties of a new penicillinase type produced by Bacteroides fragilis. Antimicrob Agents Chemother (1982) 2.27
A new technique for monitoring the behaviour of free-ranging Adélie penguins. J Exp Biol (2001) 2.24
Position of immobilization after dislocation of the glenohumeral joint. A study with use of magnetic resonance imaging. J Bone Joint Surg Am (2001) 2.24
Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology (2009) 2.23
Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes. Diabetes (1999) 2.19
Organizing and computing metabolic pathway data in terms of binary relations. Pac Symp Biocomput (1997) 2.19
Induction of inflammatory arthropathy resembling rheumatoid arthritis in mice transgenic for HTLV-I. Science (1991) 2.18
Defective beta adrenergic response of cystic fibrosis sweat glands in vivo and in vitro. J Clin Invest (1984) 2.17
Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta. Cell (2001) 2.15
Age-related changes in cell surface antigens of preleukemic AKR thymocytes. J Exp Med (1976) 2.15
Clear cell change in colorectal adenomas: its incidence and histological characteristics. Histopathology (1999) 2.15
Reevaluation of the thyroidal radioactive iodine uptake test, with special reference to reversible primary hypothyroidism with elevated thyroid radioiodine uptake. J Clin Endocrinol Metab (1988) 2.15
Penguin-mounted cameras glimpse underwater group behaviour. Proc Biol Sci (2004) 2.15
Biochemical properties of beta-lactamase produced by Legionella gormanii. Antimicrob Agents Chemother (1986) 2.10
Glutathione transferases and cancer. Crit Rev Biochem Mol Biol (1992) 2.09
Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study. J Antimicrob Chemother (2002) 2.08
In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins. Antimicrob Agents Chemother (1991) 2.08
Membrane glycoprotein CD36: a review of its roles in adherence, signal transduction, and transfusion medicine. Blood (1992) 2.06
The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest (2001) 2.05
A sharp peak of the zero-temperature penetration depth at optimal composition in BaFe2(As(1-x)P(x))2. Science (2012) 2.05
Production of 'hybrid' antibiotics by genetic engineering. Nature (1985) 2.04
Loss of E-cadherin-dependent cell-cell adhesion due to mutation of the beta-catenin gene in a human cancer cell line, HSC-39. Mol Cell Biol (1995) 2.03
Snail and SIP1 increase cancer invasion by upregulating MMP family in hepatocellular carcinoma cells. Br J Cancer (2004) 2.03
High dose rate brachytherapy for carcinoma of the uterine cervix: comparison of two different fractionation regimens. Int J Radiat Oncol Biol Phys (1995) 2.02